Compare FG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | VERA |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | 1338 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | N/A | 2021 |
| Metric | FG | VERA |
|---|---|---|
| Price | $26.50 | $42.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $31.00 | ★ $81.30 |
| AVG Volume (30 Days) | 647.6K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $5.51 | $472.48 |
| P/E Ratio | $8.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.57 | $18.76 |
| 52 Week High | $36.70 | $56.05 |
| Indicator | FG | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 54.97 |
| Support Level | $20.97 | $37.54 |
| Resistance Level | $29.63 | $42.77 |
| Average True Range (ATR) | 1.06 | 2.32 |
| MACD | 0.17 | 0.52 |
| Stochastic Oscillator | 96.77 | 53.52 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.